For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Biodesix, Inc.

Calculating rank

USPTO Granted Patents = 51

% Expired Patents = 2.0

EPO Patents = 10

Trademarks = 17

Forward Citations = 320

Loading Chart...

Loading Chart...

33 inventors (with patents filed for the assignee):

Heinrich Röder (41 out of 41 patents)

Joanna Röder (25 out of 25 patents)

Julia Grigorieva (23 out of 23 patents)

4. Maxim Tsypin (20 out of 20 patents)

5. Carlos Oliveira (11 out of 11 patents)

6. Paul Edward Kearney (7 out of 23 patents)

7. Clive Hayward (7 out of 13 patents)

8. Xiao-Jun Li (7 out of 14 patents)

9. Arni Steingrimsson (6 out of 6 patents)

10. Kenneth Charles Fang (5 out of 11 patents)

11. Krista Meyer (5 out of 5 patents)

12. Senait Asmellash (5 out of 5 patents)

13. Kevin Sayers (3 out of 3 patents)

14. Caroline Maher (3 out of 3 patents)

15. Gary A Pestano (3 out of 17 patents)

Core Competencies:

Machine Learning

Lung Cancer

Mass Spectrometry

Predictive Tests

Immunotherapy

Cancer Prognosis

Biomarkers

Patient Benefit

EGFR Pathway

Graft-Versus-Host Disease

Deep MALDI TOF

Blood-Based Sample

51 patents: Sort by Forward Citations

1. 12603182 - Interpretation of machine learning classifications in clinical diagnostics using shapley values and uses thereof (2026-04-14),

2. 12247980 - Compositions, methods and kits for diagnosis of lung cancer (2025-03-11),

3. 12230398 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2025-02-18),

4. 12094587 - Apparatus and method for identification of primary immune resistance in cancer patients (2024-09-17),

5. 11913957 - Compositions, methods and kits for diagnosis of lung cancer (2024-02-27),

6. 11894147 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2024-02-06),

7. 11710539 - Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy (2023-07-25),

8. 11621057 - Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy (2023-04-04),

9. 11594403 - Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample (2023-02-28),

10. 11542340 - Antibodies targeting pulmonary nodule specific biomarkers and uses thereof (2023-01-03),

11. 11476003 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2022-10-18),

12. 11467167 - SRM methods in Alzheimer's disease and neurological disease assays (2022-10-11),

13. 11193935 - Compositions, methods and kits for diagnosis of lung cancer (2021-12-07),

14. 11150238 - Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups (2021-10-19),

15. 10950348 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2021-03-16),

Company Overview

Biodesix, Inc. is a leading company in the field of clinical diagnostics, headquartered in Boulder, Colorado. The organization specializes in developing innovative solutions for lung cancer management, utilizing advanced technologies such as machine learning and mass spectrometry. Biodesix focuses on predictive tests and biomarkers that enhance cancer prognosis and treatment decisions, particularly in the context of immunotherapy. Their commitment to improving patient outcomes drives their research and development efforts in precision medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

51 Patents

#30 in Boulder, CO

#133 in Colorado

#6,899 in US

#13,798 in the World

Boulder, CO, United States of America

Biodesix, Inc.

Forward Citations = 320

33 inventors:

Heinrich Röder (41 out of 41 patents)

Joanna Röder (25 out of 25 patents)

Julia Grigorieva (23 out of 23 patents)

4. Maxim Tsypin (20 out of 20 patents)

5. Carlos Oliveira (11 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biodesix, Inc.. Retrieved from https://idiyas.com/company/biodesix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…